Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.56 |
| ▸ | THRA | P10827 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | PLK1 | P53350 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14161000 | 0.95 | CA1 (0.57) | RARBTHRACA1CA2PLK1 | |
| SCHEMBL6375604 | 0.86 | CA1 (0.62) | RARBCA1CA2PLK1MAPT | |
| SCHEMBL6538458 | 0.86 | PLK1 (0.69) | RARBCA1CA2PLK1MAPT | |
| SCHEMBL7323928 | 0.86 | RARB (0.63) | RARBCA1CA2PLK1HRH3 | |
| SCHEMBL19168934 | 0.86 | CA1 (0.59) | RARBCA1CA2PLK1MAPT | |
| SCHEMBL18068446 | 0.84 | CA1 (0.66) | CA1CA2PLK1MAPTALDH1A1 | |
| SCHEMBL7317986 | 0.84 | RARB (0.68) | RARBPLK1 | |
| SCHEMBL13908659 | 0.83 | PLK1 (0.73) | RARBTHRAPLK1MAPTHTT | |
| SCHEMBL17859064 | 0.83 | CA1 (0.56) | CA1CA2PLK1MAPTALDH1A1 | |
| SCHEMBL7325242 | 0.82 | RARB (0.71) | RARBPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050181988-A1 | Echinocandin cyclic peptide derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| WO-2003068807-A2 | ECHINOCANDIN CYCLIC PEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050181988-A1 | Echinocandin cyclic peptide derivatives | NGLY1, ARG1, ERG28 | RARB 4635/4885THRA 3550/4885CA1 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.